Thrombolysis after dabigatran reversal: A nation-wide Italian multicentre study, systematic review and meta-analysis.
Michele RomoliEleonora MatteoLudovica MigliaccioMauro GentileMaria Giulia MosconiGiuseppe Maria ScuraMarcello NaccaratoEnrico ColangeliPaolo CandelaresiVincenzo AndreoneFabrizio GiammelloRosa Fortunata MusolinoCristina Dell'AeraFederica Nicoletta SepeEdoardo PronelloLeonardo BarbariniMarcella CaggiulaFederica RizzoMarco PetruzzellisElisa GiorliMaria Luisa ZeddeSabrina AnticoliMarilena MangiardiMario MutoFrancesco DianaMaria Vittoria De AngelisAnna DigiovanniLetizia ConcariSara La GioiaMaria SessaSara BiguzziFrancesco CordiciMarco LongoniMaria RuggieroSilvia CenciarelliPaolo EusebiSimona SaccoValeria CasoMaurizio PaciaroniStefano RicciAndrea ZiniDanilo ToniDavid GiannandreaPublished in: European stroke journal (2022)
People treated with reperfusion strategies after dabigatran reversal with idarucizumab seem to have a marginal increase in the risk of sICH but comparable functional recovery to matched patients with stroke. Further studies are needed to define treatment cost-effectiveness and potential thresholds in plasma dabigatran concentration for reversal.
Keyphrases
- atrial fibrillation
- acute ischemic stroke
- pulmonary embolism
- cerebral ischemia
- acute myocardial infarction
- heart failure
- percutaneous coronary intervention
- combination therapy
- risk assessment
- coronary artery disease
- acute coronary syndrome
- case control
- climate change
- newly diagnosed
- brain injury
- blood brain barrier